No Data
HAOHAI BIOTEC (06826.HK) spent 0.5422 million HKD to repurchase 0.02 million shares on March 25.
On March 25, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced it spent 0.5422 million Hong Kong dollars to repurchase 0.02 million shares on March 25, 2025, with a repurchase price of 27.1-27.15 Hong Kong dollars per share.
Haohai Biological Technology's Profit Jumps 1% in 2024
Shanghai Haohai Biological Technology 2024 Annual Report: The proportion of medical aesthetics business has further increased, and the impact of policies such as centralized procurement has not yet faded.
① The medical beauty Sector achieved revenue of 1.195 billion yuan, a year-on-year increase of 13.08%, with the business proportion rising from 39.96% to 44.38%, becoming the core driving force behind the company's current performance growth. ② Compared to the "counter-trend growth" of the medical beauty Sector, multiple sectors of Shanghai Haohai Biological Technology experienced varying degrees of revenue decline, and have not yet overcome the painful adjustment period of policies.
Haohai Biotech: Summary of the 2024 Annual Report of Shanghai Haohai Biotechnology Co., Ltd.
Haohai Biotech: Shanghai Haohai Biotechnology Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Shanghai Haohai Biotechnology Co., Ltd.
Investors Interested In Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Earnings
